STOCK TITAN

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated news page for Pfizer (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pfizer's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pfizer's position in the market.

Rhea-AI Summary
Pfizer's ABRYSVO RSV vaccine receives marketing authorization in the EU for infants and older adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
-
Rhea-AI Summary
Everest Medicines announces interim results for H1 2023, with successful launch of Xerava® in China and expected approvals for Nefecon® in China and Singapore. Expenses reduced by over a third compared to last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
-
Rhea-AI Summary
FDA grants Priority Review for XTANDI in prostate cancer, decision expected in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
Rhea-AI Summary
FDA grants Priority Review for XTANDI in prostate cancer, decision expected in Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
Rhea-AI Summary
Pfizer's ABRYSVO vaccine approved by FDA for prevention of respiratory tract disease in infants caused by RSV
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) reported a 53% operational decrease in second-quarter 2023 revenues, driven by a decline in Comirnaty and Paxlovid revenues. The company narrowed its 2023 revenue guidance to $67-70 billion, maintaining its outlook for Adjusted diluted EPS of $3.25-3.45. The financial results showed a decline in reported diluted EPS of 77% and adjusted diluted EPS of 67% year-over-year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
earnings
-
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) announces the appointment of Chris Boshoff, M.D., PhD, as Chief Oncology Research and Development Officer and Executive Vice President, focusing on advancing new medicines and vaccines in oncology. Dr. Boshoff will lead Pfizer's oncology pipeline from discovery to clinical development, accelerating cancer breakthroughs globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
Rhea-AI Summary
Flagship Pioneering and Pfizer have partnered to invest $100M upfront in exploring opportunities to develop 10 single-asset programs within Pfizer's core strategic areas of interest. Pioneering Medicines, an initiative of Flagship Pioneering, will lead the exploration process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
partnership
Pfizer Inc.

NYSE:PFE

PFE Rankings

PFE Stock Data

157.31B
5.64B
0.05%
69.96%
1.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About PFE

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.